The consortium is a collaboration between the Carpenter Lab, the Genetic Perturbation Platform, and the Center for the Development of Therapeutics at the Broad Institute of MIT and Harvard along with industry and non-profit partners that are committed to creating a public Cell Painting dataset containing both genetic and chemical perturbations. With such a resource, each company or institution could then create its own proprietary Cell Painting data in-house, while matching their profiles against the public set, to guide small molecules’ progression to the clinic.
- Janssen Pharmaceutica NV
- Merck KGaA, Darmstadt, Germany
- Takeda Pharmaceutical Company Limited (“Takeda”)